4.7 Article

cPLA2α activates PI3K/AKT and inhibits Smad2/3 during epithelial-mesenchymal transition of hepatocellular carcinoma cells

期刊

CANCER LETTERS
卷 403, 期 -, 页码 260-270

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2017.06.022

关键词

Metastasis; Phospholipase; Lipid metabolism; EGF; TGF-beta

类别

资金

  1. National Natural Science Foundation of China [81201646, 81472683]
  2. The National High Technology Research and Development Program of China (863 Program) [2015AA020403]
  3. NSFC-FRQS program [81661128009]
  4. National Key Research and Development Program [2016YFC0900100]
  5. National Key Scientific Instrument and Equipment Development Project [2013YQ16055106]

向作者/读者索取更多资源

Cytosolic phospholipase A2 alpha (cPLA2 alpha), a key phospholipase that regulates lipid metabolism, plays an important role in tumor progression. In the present study of hepatocellular carcinoma (HCC), cPLA2 alpha was overexpressed in highly metastatic HCC cell lines. Immunohistochemical staining showed increased levels of cPLA2 alpha at the invasive edges of HCC, and a clinicopathological analysis of samples from 111 patients revealed that its expression level was linked with micro-vascular invasion and cirrhosis. Knockdown of cPLA2 alpha inhibited migration, probably due to its role in actin polymerization. Overexpression of cPLA2 alpha promoted cell migration and invasion. Based on the mechanistic analysis, our data suggested that cPLA2 alpha mediate epidermal growth factor (EGF) induced epithelial-mesenchymal transition (EMT) through PI3K/AKT/ERK pathway. cPLA2 alpha activity was required for the transforming growth factor-(TGF)-beta-induced EMT. However, cPLA2 alpha inhibited Smad2/3 activation and promoted the activation of the PI3K/AKT/ERK pathway. A xenograft tumor transplant model confirmed the role of cPLA2 alpha in HCC invasion and metastasis. Based on the mechanistic analysis, cPLA2 alpha mediated both EGF- and TGF-beta-induced EMT, which are essential for HCC metastasis. cPLA2 alpha is a potentially target for novel therapies of HCC. (C) 2017 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据